NEW YORK, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL) today announced the appointment of John Harrison, PhD, to its Scientific Advisory Board. Dr. Harrison is an internationally acknowledged specialist for design of human clinical outcome measurement in Alzheimer's disease and other cognitive impairments.
"Dr. Harrison brings an extensive experience in cognitive testing for clinical trials to our Scientific Advisory Board," said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. "I believe Dr. Harrison's insight and guidance will contribute significantly to our trial design and drug development initiatives, and I am delighted to welcome him to the Anavex team."
Dr. Harrison has successfully integrated cognitive testing into drug development programs for many pharmaceutical and biotechnology companies including eight of the current 'Fortune' top 10 pharmaceutical companies. He is Honorary Senior Lecturer in the Department of Medicine at Imperial College in London, focusing on investigating cognitive change that may show disease progression in Alzheimer's and other related indications. Dr. Harrison is a member of the American Psychological Association, holds Chartered Psychologist status with the British Psychological Society and Chartered Scientist status with the UK Science Council. He has authored/co-authored more than 60 books and scientific articles and has been invited as a specialist for cognitive tests at many international meetings, including the European Task Force for Alzheimer's disease and American Alzheimer's Association roundtable events.
"Since being introduced to Anavex, it has become apparent to me how potentially significant the Company's science could be for the future of Alzheimer's and other CNS diseases," said Dr. Harrison. "I am excited to apply my area of interest, the measurement of cognitive change in clinical drug trials, to the advancement of Anavex's promising pipeline and look forward to serving on the Company's Scientific Advisory Board."
Dr. Harrison's background also includes prior positions as Head of Neuropsychology at CeNeS Pharmaceuticals, Principal Consultant at CPC Pharma Services, and Principal Scientist at CogState Ltd. In addition to his current academic appointment, he is principal consultant at Metis Cognition Ltd and holds a PhD in neuroscience from the University of London.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. ( www.anavex.com ) is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer's, CNS diseases and various types of cancer. ANAVEX 2-73, an orally available drug candidate developed to treat Alzheimer's through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties. A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and Aricept® (donepezil). The combined therapeutics produced up to 80% greater reversal of memory loss in Alzheimer's disease models versus when the drugs were used individually. Anavex is a publicly traded corporation quoted as AVXL.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company's most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Anavex Life Sciences Corp. Research & Business Development Email: Shareholder & Media Relations Toll-free: 1-866-505-2895 Outside North America: +1 (416) 489-0092 Email: www.anavex.com
